The firm has “high confidence” that SER-252 will at least match the efficacy observed with other apomorphine delivery approaches, such as Supernus’ (SUPN) recently approved Onapgo ...

Supernus Pharmaceuticals stock opened at $33.05 on Monday. Supernus Pharmaceuticals has a 12 month low of $25.53 and a 12 month high of $40.28. The stock has a fifty day simple moving average of ...

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a research note released on Tuesday morning. Separately ...

Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN). The branded pharmaceutical industry relies on a high-cost, high-reward business model ...

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals ...

In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands against the other cash-rich small cap stocks. Small-cap stocks in the US have been under ...

Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson's disease therapies to its stable.

Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) Meningococcal vaccine For active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in ...